공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

인터류킨 17A : 파이프라인 리뷰

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016

리서치사 Global Markets Direct
발행일 2016년 09월 상품 코드 374378
페이지 정보 영문 76 Pages
가격
US $ 3,500 ₩ 3,913,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 7,827,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 11,741,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


인터류킨 17A : 파이프라인 리뷰 Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016
발행일 : 2016년 09월 페이지 정보 : 영문 76 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

인터류킨 17A(Interleukin 17A)를 표적으로 한 치료제 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

서론

  • 조사 범위

인터류킨 17A 개요

치료제 개발

  • 개발중인 제품 : 개발 단계별
  • 개발중인 제품 : 치료 영역별
  • 개발중인 제품 : 증상별

파이프라인 제품 개요

  • 후기 단계 제품
  • 초기 단계 제품

기업에서 개발중인 제품

치료제 평가

  • 단독치료 제품(Monotherapy Products)/병용요법 제품(Combination Products)별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개발 참여 기업

  • AbbVie Inc
  • Abeome Corporation
  • Affibody AB
  • Cell Medica Limited
  • Eli Lilly and Company
  • Johnson & Johnson
  • Merck KGaA
  • Novartis AG
  • Orega Biotech SAS

약제 개요

휴지 상태인 프로젝트

개발이 중지된 제품

주요 뉴스 및 프레스 릴리스

부록

도표

LSH 16.10.24

Summary:

Global Markets Direct's, 'Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016', provides in depth analysis on Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A)
  • The report reviews Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) Overview
  • Therapeutics Development
    • Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Products under Development by Stage of Development
    • Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Products under Development by Therapy Area
    • Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Products under Development by Indication
  • Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Products under Development by Companies
  • Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Abeome Corporation
    • Affibody AB
    • Cell Medica Limited
    • Eli Lilly and Company
    • Johnson & Johnson
    • Merck KGaA
    • Novartis AG
    • Orega Biotech SAS
  • Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Drug Profiles
    • ABT-122 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ABY-035 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CNTO-6785 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DLX-2882 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DLX-2907 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DLX-2909 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ixekizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-1095 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit IL-17A for Psoriasis and Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OREG-203 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • secukinumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Dormant Projects
  • Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Discontinued Products
  • Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Featured News & Press Releases
    • Aug 04, 2016: NICE draft guidance recommends new drug for people with ankylosing spondylitis
    • Jun 21, 2016: Health Canada approval of Taltz (ixekizumab) Brings Targeted Therapy to Canadians Living with Moderate-to-Severe Plaque Psoriasis
    • Jun 09, 2016: New drug clears psoriasis in clinical trials
    • Jun 08, 2016: Studies Demonstrate Lilly's Taltz (Ixekizumab) Maintained Or Achieved High Levels Of Skin Clearance For Patients With Moderate-To-Severe Plaque Psoriasis Through 60 Weeks: Results Published In The New England Journal Of Medicine
    • Jun 08, 2016: Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016
    • Jun 07, 2016: Eli Lilly and Company Announces Data on Ixekizumab At Annual European Congress Of Rheumatology
    • Jun 07, 2016: Tampa Dermatologist Launches Clinical Trial for Psoriatic Arthritis Patients
    • Jun 02, 2016: AbbVie Announces Presentation on ABT-122 at the Annual European Congress of Rheumatology
    • May 04, 2016: Affibody Announces Initial Results from a Phase I Study of ABY-035
    • May 02, 2016: Lilly's Taltz (Ixekizumab) Now Available In The U.S. For The Treatment Of Moderate-To-Severe Plaque Psoriasis
    • Apr 27, 2016: COSENTYX - first Interleukin-17A inhibitor for psoriatic arthritis and ankylosing spondylitis approved by Health Canada
    • Apr 26, 2016: Lilly announces European Commission approval for plaque psoriasis drug
    • Apr 23, 2016: OptiMed Specialty Pharmacy to Distribute Cosentyx
    • Apr 05, 2016: Diplomat Announces TALTZ Availability for the Treatment of Plaque Psoriasis
    • Mar 22, 2016: Lilly's Taltz (Ixekizumab) Receives U.S. FDA Approval For The Treatment Of Moderate-To-Severe Plaque Psoriasis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by AbbVie Inc, H2 2016
  • Pipeline by Abeome Corporation, H2 2016
  • Pipeline by Affibody AB, H2 2016
  • Pipeline by Cell Medica Limited, H2 2016
  • Pipeline by Eli Lilly and Company, H2 2016
  • Pipeline by Johnson & Johnson, H2 2016
  • Pipeline by Merck KGaA, H2 2016
  • Pipeline by Novartis AG, H2 2016
  • Pipeline by Orega Biotech SAS, H2 2016
  • Dormant Projects, H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top
전화 문의
F A Q